AstraZeneca has launched two new trials with its SGLT-2 inhibitor Forxiga (dapagliflozin) exploring its potential beyond the drug's approved diabetes indication.

The Anglo-Swedish drugs giant has kicked off two randomised, placebo-controlled Phase IIIb outcome trials assessing Forxiga in the management of chronic kidney disease and chronic heart failure, in people with and without type-2 diabetes.

This marks the first time a major outcomes study will evaluate the effect of an SGLT-2 inhibitor in chronic kidney disease, for which there are currently few treatment options and a significant unmet medical need, the firm noted.

AZ said it has also initiated a stream of new mechanistic trials designed to understand the underlying science behind the potential cardiovascular and renal protective signals seen with the SGLT-2 inhibitor class.

"Our transformative clinical research aims to address the multiple risk factors associated with cardiovascular morbidity and mortality, including diabetes, chronic heart failure and chronic kidney disease. By following the science, we are seeking to improve outcomes for millions of patients with cardiovascular disease around the world," said Elisabeth Björk, head of Cardiovascular and Metabolic Diseases, Global Medicines Development.